127,353 research outputs found
Letter from J. Emory & B. Waugh to James B. Finley
No full textJohn Emory and Beverly Waugh [book agents appointed to the Methodist Book Concern,1828-1832] send an invoice to Finley for $29.77. This account for subscriptions to the 1824 and 1825 Methodist Magazine is still open and needs to be closed. If someone else is responsible for payment, Emory and Waugh ask Finley to let them know. Abstract Number - 566https://digitalcommons.owu.edu/finley-letters/1862/thumbnail.jp
Letter from Lorenzo Waugh to James B. Finley
No full textRev. Lorenzo Waugh has transferred from the Ohio Conference to the Missouri Conference [appointed to Farmington Circuit, Cape Girardeau District, St. Francois County]. There have been fears of a slave rebellion. Last night, people spent the night vigilantly armed in anticipation of a revolt which thankfully never happened. The curse of slavery has been rendered worse by abolitionism. Slaves in Missouri have more liberty, are in good health, and armed. Thus, folks here have more reason to fear a slave rebellion than those living in slave states. There is much drinking, gambling and horse-racing in the towns. Folks on the circuit are lukewarm and indifferent church members. Nevertheless, he feels called by God to serve here. Abstract Number - 796https://digitalcommons.owu.edu/finley-letters/2301/thumbnail.jp
George F. Waugh, approximately 1900-1905
No full textPhotographic portrait of George F. Waugh in his West Point cadet uniform, approximately 1900-1905.George Waugh attended Norwich University for one year as a member of the Class of 1901. He left Norwich to enlist with the 6th Massachusetts Volunteer Infantry in 1898. After his service in the Spanish-American War, he entered West Point, graduating in 1905
Going Beyond Counting First Authors in Author Co-citation Analysis
No full textThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
The voice of authority : Evelyn Waugh's fiction
No full textA large part of the extant criticism of Evelyn Waugh's fiction is orientated
towards either a biographical or a literary-historical interest: there are
comparatively few detailed surveys of the novels themselves. This study
attempts such a survey, and in particular examines the tension which inheres
in the relationship of Waugh's poised, urbane narrators to the social and
moral chaos they depict. I have been interested in the source and management
of that poise, the testing, as it were to destruction, of a series of
narrative positions. There is a very modern equation to be observed in
Waugh's fiction, between the potentially anarchic mode of fiction and what
Waugh felt to be the actual anarchy of contemporary civilisation. His
novels can with interest be read in terms of a comic exploitation of this
equation, and subsequently, as the writer aged, of his attempts to evade
its logic, to discover a 'voice of authority'. Apparently secure narrative
stances are repeatedly undermined, and a succession of 'realities'
compromised - Tony Last's, William Boot's, John Plant's, Guy Crouchback's.
It is this awareness and exploitation of the reflexive quality of fiction,
and its use in disclosing the nature of his age which lends Waugh's writing
its real and enduring interest.
I seek to draw out this awareness through detailed examination of the
different novels' precise narrative stance, the source of their 'voice',
and have been largely content to let stand other commentators' descriptions
of Waugh's broader thesis. My method involves close attention to Waugh's
language, from the conviction that nuances of tone and the development of
marginal allusions and metaphors are the keys to many of his characteristic
effects
Dispelling the Myths Behind First-author Citation Counts
No full textWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
Modelling and evaluation of pulsed and pulse phase thermography through application of composite and metallic case studies
No full textA transient thermal finite element model has been created of the pulsed thermography (PT) and pulse phase thermography (PPT) experimental procedure. The model has been experimentally validated through the application of four case studies of varying geometries and materials. Materials used include aluminium, carbon fibre reinforced plastic (CFRP) and adhesively bonded joints. The same four case studies have also formed a basis for comparison between three experimental techniques: PT, PPT and the more established ultrasonic (UT) c-scan.Results show PPT to be advantageous over PT due to its deeper probing as it is less influenced by surface features. Whilst UT is able to reveal all the defects in these case studies, the time consuming nature of the process is a significant disadvantage compared to the full field thermography methods.Overall, the model has achieved good correlation for the case studies considered and it was found that the main limiting factor of the PT model accuracy was knowledge of thermal material properties such as conductivity and specific heat. Where these properties were accurately known the model performed very well in comparison with experimental results. PPT modelling performed less well due to the method of processing the PT data which aims to emphasise small differences. Hence inaccuracies in inputted values such as material properties have a much greater influence on the modelled PPT data. The model enables a better understanding of PT and PPT and provides a means of establishing the experimental set-up parameters required for different components, allowing the experimental technique to be appropriately tailored to more complex situations including bonded joints or structures where several materials are present.The paper ends with a section on defect detectability based on thermal diffusivity contrast between the defect and the bulk material. It shows that in aluminium, because of its higher conductivity, greater thermal contrast is achieved for small differences in diffusivity. Regions where the diffusivity ratio between defect and bulk materials was insufficient to provide thermal contrast for defect identification were found. PPT phase data is shown to reduce the extent of such regions increasing the detectability of defects. Effusivity is introduced as a means of determining the thermal contrast between the defect and non-defective areas and hence establishing the defect detectability
The nosological status of early onset anorexia nervosa
No full textBackground: although cases of early onset anorexia nervosa have been described, there has been no systematic comparison of early onset cases with classic cases of later onset, or with other forms of early onset eating disturbance.Method: a consecutive series of patients referred to two specialist child and adolescent eating disorder services with a clinical diagnosis of eating disorder (N = 126) was systematically assessed using a child version of the Eating Disorder Examination (EDE) and the K-SADS interview.Results: of 86 patients with a diagnosis of eating disorder of early onset, 38 received a clinical diagnosis of anorexia nervosa (AN). The remainder were mainly diagnosed as having food avoidance emotional disorder (25 patients) and selective eating (17 patients). Six received other diagnoses (bulimia nervosa, or functional dysphasia). These 48 patients were combined to form a group of early onset non-AN eating disturbance. In terms of specific eating disorder psychopathology and general psychopathology, the early onset AN group was very similar to the late onset AN sample. When the two early onset groups were compared, there was a marked difference between them in terms of eating disorder psychopathology. A discriminant function analysis using the EDE information produced a clear discrimination, with the EDE restraint and shape concern subscales doing most of the discrimination work.Conclusions: the specific psychopathology of AN of early onset is very similar to that of classic adolescent onset AN. Other forms of early onset eating disorder do not evidence this specific psychopatholog
Dasyhelea stemlerae Waugh and Wirth
No full text<i>Dasyhelea stemlerae</i> Waugh and Wirth <p> <i>Dasyhelea stemlerae</i> Waugh and Wirth, 1976: 233 (Maryland); Wilkening et al. 1985: 519 (Florida records); Borkent and Grogan 2009: 11 (in Nearctic catalog; distribution).</p> <p> <b>Discussion.</b> Wilkening et al. (1985) only listed this species from Alachua Co. (paratypes). We provide the first record from Wakulla Co.</p> <p> <b>New records.</b> Wakulla Co., Wakulla Springs St. Pk., 25-26-V-2004, S. Murphree, CDC LT, swamp on Lodge Rd., 1 female (WLGC).</p>Published as part of <i>William L. Grogan, Jr., Hribar, Lawrence J., Murphree, C. Steven & Cilek, James E., 2010, New records of biting and predaceous midges from Florida, including species new to the fauna of the United States (Diptera: Ceratopogonidae), pp. 1-59 in Insecta Mundi 2010 (147)</i> on page 24, DOI: <a href="http://zenodo.org/record/5352908">10.5281/zenodo.5352908</a>
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer
No full textBACKGROUND:
The incidence of lung cancer is declining following a drop in smoking rates, but it is still the leading cause of death from cancer in England and Wales, with about 30,000 deaths a year. Survival rates for lung cancer are poor everywhere, but they appear to be better in the rest of the European Community and the USA than in the UK. Only about 5 per cent of people with lung cancer survive for 5 years, and nearly all of these are cured by surgery after fortuitously early diagnosis. At present, only a small proportion of patients (probably about 5 per cent) with non-small-cell lung cancer are being given chemotherapy. Some centres treat a greater proportion.
OBJECTIVES:
This review examines the clinical effectiveness and cost-effectiveness of four of the newer drugs - vinorelbine, gemcitabine, paclitaxel and docetaxel - used for treating the most common type of lung cancer (non-small-cell lung cancer). The first three drugs are used for first-line treatment, but at present docetaxel is used only after first-line chemotherapy has failed.
METHODS:
This report was based on a systematic literature review and economic modelling, supplemented by cost data. RESULTS - NUMBER AND QUALITY OF STUDIES: A reasonable number of randomised trials were found - three for docetaxel, six for gemcitabine, five for paclitaxel and 13 for vinorelbine. The quality of the trials was variable but good overall. There was a wide range of comparators. Some trials compared chemotherapy with best supportive care (BSC), which involves care that aims to control symptoms, with palliative radiotherapy if needed, but not to prolong life. Others compared the newer drugs against previous drugs or combinations. RESULTS - SUMMARY OF BENEFITS: The gains in duration of survival with the new drugs are modest - a few months - but worthwhile in a condition for which the untreated survival is only about 5 months. There are also gains in quality of life compared with BSC, because on balance the side-effects of some forms of chemotherapy have less effect on quality of life than the effects of uncontrolled spread of cancer. RESULTS - COSTS: The total cost to the NHS of using these new drugs in England and Wales might be about GBP 10 million per annum, but is subject to a number of factors. There would be non-financial constraints on any increase in chemotherapy for the next few years, such as staffing; the number of patients choosing to have the newer forms of chemotherapy is not yet known; and the costs of the drugs may fall, for example, as generic forms appear. RESULTS - COST PER LIFE-YEAR GAINED: The available data did not provide an entirely satisfactory basis for cost-effectiveness calculations. The main problem was the lack of direct comparisons of the new drugs. In order to strengthen the analysis, three different modelling approaches were used: pairwise comparisons using trial data; cost-minimisation analysis, as if all the new regimens were of equal efficacy; and cost-effectiveness analysis pooling the results of several trials with different comparators, giving indirect comparisons of the new drugs by using BSC as the common comparator. A number of different scenarios were explored through extensive sensitivity analysis in each model. Outcomes were expressed in incremental cost per life-year saved or incremental cost, versus BSC. There was insufficient evidence from which to derive cost per quality-adjusted life-year. In first-line treatment, vinorelbine, gemcitabine, and the lower-dose paclitaxel plus cisplatin combinations generally performed well against BSC under a range of different scenarios and especially when given as a maximum of 3 cycles. Incremental cost per life-year gained (LYG) versus BSC varied depending on scenario, but baseline figures based on trial data and protocols were: single-agent vinorelbine, pound 2194 per LYG; vinorelbine plus cisplatin, pound 5206; single-agent gemcitabine, pound 5690; gemcitabine plus cisplatin, pound 10,041; and paclitaxel plus cisplatin, pound 8537. In second-line chemotherapy, docetaxel gave a cost per LYG of pound 17,546, again well within the range usually accepted as cost-effective. However, in routine care, the impact of therapy would be regularly reviewed, and continuation would depend on response, side-effects, patient choice and clinical judgement. Chemotherapy would be stopped in non-responders, making chemotherapy more cost-effective. A 'real-life' scenario in which 60 per cent of patients receive only 1 or 2 cycles of chemotherapy gives much lower costs per LYG, with single-agent gemcitabine, single-agent vinorelbine, and paclitaxel plus platinum appearing to be cost-saving compared with BSC; the incremental cost of gemcitabine plus cisplatin would be pound 2478 per LYG, and of vinorelbine plus cisplatin, pound 2808. At the very least, gains in duration of survival were achieved without diminution of quality of life (at best, they improved quality) and with relatively low incremental cost. Comparisons among the individual drugs should be viewed with caution because they have had to be based on indirect comparisons. RESULTS - LIMITATIONS OF THE ANALYSIS: Each of the three models had limitations. The cost-effectiveness estimates from the pairwise comparisons were based on single studies. The cost-minimisation analysis assumed that the regimens have equal efficacy in practice. The cost-effectiveness analysis had to be based on pooling data from individual trials. The costs of BSC, inpatient stay and outpatient visits were from Scottish data. Median rather than mean data on duration of survival have been used in the analysis, because most of the trials reported only median data. Median survival and number of drug cycles were calculated by averaging across a number of studies, rather than being reliant on one particular study. The costs of the less expensive antiemetics cited in the trials were omitted. The use of more modern and costly antiemetics would have a modest detrimental effect on cost-effectiveness. In the absence of published data, an estimate was made of the cost of side-effects of chemotherapy, in particular hospital admissions, and applied to all the new regimens. In practice, admissions related to side-effects and their respective costs are likely to vary by regimen.
CONCLUSIONS:
The new drugs for non-small-cell lung cancer extend life by only a few months compared with BSC, but appear to do so without net loss in quality of life and at a cost per LYG that is much lower than for many other NHS activities. Depending on assumptions used, these new drugs range from being cost-effective, as conventionally accepted, to being cost-saving. CONCLUSIONS - IMPLICATIONS OF THE NEWER DRUGS: One of the present constraints on chemotherapy is availability of inpatient beds. The advent of newer and gentler forms of chemotherapy given on an outpatient basis would not only overcome this, but it would allow more patients to be treated. This might apply particularly to older patients. The treatment of more patients would increase workload for oncologists, cancer nurses and pharmacists. The Government has already announced increased expenditure on staff for cancer care. The previously pessimistic attitudes to chemotherapy in non-small-cell lung cancer are changing in the wake of the newer agents, and this shift is likely to increase referral. CONCLUSIONS - NEED FOR FURTHER RESEARCH: Recent advances in chemotherapy are welcome, but their effects remain small for patients with non-small-cell lung cancer. Much more research is needed into better drugs, better combinations, new ways of assessing the likelihood of response and especially direct comparisons between the new regimens. This research would be aided by having a greater proportion of patients involved in trials, but there will be infrastructure implications of increased participation
- …
